Prosecution Insights
Last updated: April 19, 2026

Shanghai Epiprobe Biotechnology Co. Ltd.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
3
Final Rejections
3
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18041495 KIT AND METHOD FOR DETECTING NUCLEIC ACID AND USES THEREOF SWITZER, JULIET CAROLINE 1682 Non-Final OA Feb 13, 2023
17594792 METHYLATION-BASED MODIFIED TUMOR MARKER STAMP-EP8 AND APPLICATION THEREOF DAUNER, JOSEPH G 1682 Final Rejection May 20, 2022
17309901 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP4 HANEY, AMANDA MARIE 1682 Final Rejection Feb 14, 2022
17309902 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP6 BUCHANAN, BAILEY CHEYENNE 1682 Non-Final OA Feb 14, 2022
17309898 TUMOR MARKER STAMP-EP3 BASED ON METHYLATION MODIFICATION BUCHANAN, BAILEY CHEYENNE 1682 Non-Final OA Dec 14, 2021
17250457 METHYLATION MODIFICATION-BASED TUMOR MARKER STAMP-EP1 GIAMMONA, FRANCESCA FILIPPA 1681 Final Rejection Sep 13, 2021

Managing Shanghai Epiprobe Biotechnology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month